Looking at a stock in the context of an analyst’s price target can be a tricky endeavor. #-ad_banner-#Most analysts place such targets in the context of where they believe shares will trade in a quarter or two. And that’s not really how you should look at a stock. The focus on near-term quarterly results can be too short-sighted. The most profitable style of investing is to focus on stocks that possess considerable upside (or downside) a year or two down the road. Still, I monitor analysts’ price targets anyway, often in search of a big gap between the current price… Read More
Looking at a stock in the context of an analyst’s price target can be a tricky endeavor. #-ad_banner-#Most analysts place such targets in the context of where they believe shares will trade in a quarter or two. And that’s not really how you should look at a stock. The focus on near-term quarterly results can be too short-sighted. The most profitable style of investing is to focus on stocks that possess considerable upside (or downside) a year or two down the road. Still, I monitor analysts’ price targets anyway, often in search of a big gap between the current price and the target. Anytime you see an analyst suggest a stock is worth 50% or even 100% more than the current share price, it’s surely worth further research. Here are three such stocks that could surge far higher — if analysts are on the mark with their predictions. 1. ZS Pharma (Nasdaq: ZSPH ) When it comes to pulling off an IPO, timing is everything. A broad range of young biotech companies came public early this year, only to get wiped out in a late winter rout. Many of the biotech stocks that swooned back then are only now regaining… Read More